Download PDF
Pharmacopsychiatry 2004; 37(2): 69-73
DOI: 10.1055/s-2004-815528
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Relationship between Haloperidol Plasma Concentration, Debrisoquine Metabolic Ratio, CYP2D6 and CYP2C9 Genotypes in Psychiatric Patients

Adrián LLerena1 , 2 , 3 , Alfredo de la Rubia2 , Roland Berecz1 , Pedro Dorado1
  • 1Department of Pharmacology and Psychiatry, Faculty of Medicine, University of Extremadura, Badajoz, Spain
  • 2Unit of Research and Clinical Psychopharmacology, Psychiatric Hospital, Mérida
  • 3Department of Medical Sciences, Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal
This study was supported partly by a grant from the Spanish Ministry of Health, Instituto Carlos III (FIS 01/0699) and coordinated under the frame of the Hungarian-Spanish S&T Cooperation Programme (E-45/2001)
Further Information

Publication History

Received: 7.10.2002 Revised: 30.1.2003

Accepted: 26.2.2003

Publication Date:
29 March 2004 (online)

Also available at
    Permissions and Reprints

Background: Around seven percent of Caucasians are poor metabolizers of cytochrome P450, CYP2D6 due to genetically impaired activity of the enzyme. Haloperidol in vitro and in vivo inhibits the activity of CYP2D6 and also the involvement of the enzyme in haloperidol metabolism has been reported. The present study was aimed to evaluate the possible inhibition of CYP2D6 during haloperidol treatment, and to determine the effect of CYP2D6 and CYP2C9 genotypes on the plasma concentration of haloperidol. Methods: Thirty Caucasian psychiatric patients under haloperidol monotherapy were studied. CYP2D6 activity was evaluated by the debrisoquine metabolic ratio (MR), subjects with MR > 12.6 were named as poor metabolizers. Haloperidol plasma concentration was determined by high performance liquid chromatography. Results: The number of patients with debrisoquine MR > 12.6 was higher than the expected comparing to healthy volunteers (13 % vs. 6.6 %, respectively). Debrisoquine MR was correlated with the dose of haloperidol (r = 0.40, p < 0.05), and also with the plasma concentration (r = 0.58, p < 0.001). Additionally, three patients comedicated with inhibitors of CYP2D6 were studied, all of them had a debrisoquine MR > 12.6, however only one was genetically poor metabolizer of CYP2D6. CYP2D6 and CYP2C9 genotypes were not related to the dose or plasma concentration of haloperidol. Conclusions: The present data support the dose-dependent inhibitory effect of haloperidol on CYP2D6, and the influence of this enzyme activity on haloperidol plasma concentration under steady-state conditions. The inhibitory effect of haloperidol on CYP2D6 enzyme activity may result in drug interactions and unexpected high plasma concentrations when drugs metabolized by the same enzyme are given concomitantly with haloperidol.

References

  • 1 Avenoso A, Spina E, Campo G, Facciola G, Ferlito M, Zuccaro P ,. et al . Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications.  Pharmacol Res. 1997;  35 335-339
    PubMedGoogle Scholar
  • 2 Benítez J, LLerena A, Cobaleda J. Debrisoquine oxidation polymorphism in a Spanish population.  Clin Pharmacol Ther. 1988;  44 74-77
    PubMedGoogle Scholar
  • 3 Berecz R, LLerena A, De La Rubia A, Gómez J, Kellermann M, Dorado P ,. et al . Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients.  Pharmacopsychiatry. 2002;  35 231-234
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Dahl M L. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics.  Clin Pharmakokinet. 2002;  41 453-470
    PubMedGoogle Scholar
  • 5 Dorado P, Norberto M, Berecz R, Martínez M, de la Rubia A, Yasar Ü ,. et al . CYP2C9 genotype and diclofenac hydroxylation in a Spanish population.  Pharmacol Toxicol. 2001;  89 Suppl 1 102
    PubMedGoogle Scholar
  • 6 Goff D C, Midha K K, Brotman A W, Waites M, Baldessarini R J. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine.  Am J Psychiatry. 1991;  148 790-792
    PubMedGoogle Scholar
  • 7 Gram L F, Debruyne D, Caillard V, Boulenger J P, Lacotte J, Moulin M ,. et al . Substantial rise in sparteine metabolic ratio during haloperidol treatment.  Br J Clin Pharmacol. 1989;  27 272-275
    PubMedGoogle Scholar
  • 8 Inaba T, Jurima M, Mahon W A, Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.  Drug Metab Dispos. 1985;  13 443-448
    PubMedGoogle Scholar
  • 9 Kohnke M D, Griese E U, Stosser D, Gaertner I, Barth G. Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone.  Pharmacopsychiatry. 2002;  35 116-118
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update.  Clin Pharmacokinet. 1999;  37 435-456
    PubMedGoogle Scholar
  • 11 Ledesma M C, Agúndez J AG, Lozano L, LLerena A, Benítez J. The CYP2D6 polymorphism is not a relevant factor on steady-state haloperidol plasma levels. Abstract to Clinical Pharmacology in Psychiatry Conference. Badajoz; 1997. October 23 - 25
    Google Scholar
  • 12 LLerena A. Metabolización hepática de fármacos: Interacciones genético-ambientales en el fenotipo de debrisoquina. Doctoral Thesis. University of Extremadura Badajoz. Spain; 1988
    Google Scholar
  • 13 LLerena A, Alm C, Dahl M -L, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.  Ther Drug Monit. 1992;  14 92-97
    PubMedGoogle Scholar
  • 14 LLerena A, Dahl M L, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor metabolizers.  Therapeutic Drug Monitoring. 1992;  14 261-264
    PubMedGoogle Scholar
  • 15 LLerena A, Herraiz A G, Cobaleda J, Johansson I, Dahl M -L. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.  Clin Pharmacol Ther. 1993;  54 606-611
    PubMedGoogle Scholar
  • 16 LLerena A, Cobaleda J, Martínez C, Benítez J. Interethnic differences in drug metabolism: influence of sex-related and environmental factors on debrisoquine hydroxylation phenotype.  Eur J Drug Metab Pharmacokinet. 1996;  21 129-138
    PubMedGoogle Scholar
  • 17 LLerena A, Berecz R, de la Rubia A, Dorado P. QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy.  European Journal of Clinical Pharmacology. 2002a ;  58 223-224
    CrossrefPubMedGoogle Scholar
  • 18 LLerena A, Berecz R, de la Rubia A, Dorado P. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients.  J Psychopharmacol.. 2002b;  16 359-362
    PubMedGoogle Scholar
  • 19 Mahr G C, Berchou R, Balon R. A grand mal seizure associated with desipramine and haloperidol.  Can J Psychiatry. 1987;  32 463-464
    PubMedGoogle Scholar
  • 20 Miners J O, Birkett D J. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.  Br J Clin Pharmacol. 1998;  45 525-538
    CrossrefPubMedGoogle Scholar
  • 21 Müller-Siecheneder F, Müller M J, Hillert A, Szegedi A, Wetzel H, Benkert O. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome.  J Clin Psychopharmacol. 1998;  18 111-120
    CrossrefPubMedGoogle Scholar
  • 22 Pan L, Vander Stichele R, Rosseel M T, Berlo J A, De Schepper N, Belpaire F M. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients.  Ther Drug Monit. 1999;  21 489-497
    CrossrefPubMedGoogle Scholar
  • 23 Roh H K, Chung J Y, Oh D Y, Park C S, Svensson J O, Dahl M L,. et al . Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.  Br J Clin Pharmacol. 2001;  52 265-271
    CrossrefPubMedGoogle Scholar
  • 24 Shin J G, Kane K, Flockhart D A. Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol.  Br J Clin Pharmacol. 2001;  51 45-52
    CrossrefPubMedGoogle Scholar
  • 25 Stormer E, Brockmoller J, Roots I, Schmider J. Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro.  Psychopharmacology (Berl). 2000;  151 312-320
    CrossrefPubMedGoogle Scholar
  • 26 Syvalahti E K, Lindberg R, Kallio J, De Vocht M. Inhibitory effects of neuroleptics on debrisoquine oxidation in man.  Br J Clin Pharmacol. 1986;  22 89-92
    PubMedGoogle Scholar
  • 27 Ulrich S, Neuhof S, Braun V, Meyer F P. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder.  Pharmacopsychiatry. 1998;  31 163-169
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T ,. et al . Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients.  Pharmacol Res. 1995;  31 347-353
    PubMedGoogle Scholar
  • 29 Yasar Ü, Eliasson E, Dahl M L, Johansson I, Ingelman-Sundberg M, Sjöqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254 : 628 - 631.  Erratum in: Biochem Biophys Res Commun. 1999;  258 227
    PubMedGoogle Scholar
  • 30 Young D, Midha K K, Fossler M J, Hawes E M, Hubbard J W, McKay G ,. et al . Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6.  Eur J Clin Pharmacol. 1993;  44 433-438
    CrossrefPubMedGoogle Scholar

Dr. Adrián LLerena

Faculty of Medicine

University of Extremadura

Av. de Elvas s/n

E-06071 Badajoz (Spain)

Phone: +34 924 289467

Fax: +34 924 289467

Email: allerena@unex.es